NervGen Pharma Reports 2021 Year End Results and Provides Update on Phase 1 Study

Vancouver, Canada. February 28, 2022 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended December 31, 2021. “We have continued to make important progress […]

Five Things Emergency Department Staff Should Know About Spinal Cord Injury

By Codi Darnell January 25, 2022 Deciding to seek care at an emergency department isn’t usually a decision people make lightly. Who wants to sit around for hours in a lineup of assorted symptoms, drowning in the smells of bodily fluids vaguely masked by latex and isopropyl alcohol? Not most people. But heading to the […]

NervGen Pharma Applauds President Biden Signing Defense Bill / Department of Defense now able to Move Forward on Brain Plasticity Research

Cincinnati, Ohio January 4, 2022 – NervGen Pharma Corp., through its subsidiary, NervGen US Inc., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, applauds President Biden for signing the Fiscal Year 2022 National Defense Authorization Act (FY22 NDAA) into law on December […]

Balancing Health and the Holidays

By Codi Darnell December 14, 2021 ‘Tis the season for twinkle lights, traditions and totally neglecting the management of our chronic conditions. Yes, the holiday season is upon us. Calendars fill up quickly with school concerts, work parties, family dinners and friend get-togethers. Not to mention the shopping, wrapping, cookie decorating and Hallmark movie watching. […]

NervGen Pharma Corp. Closes Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada. November 29, 2021— NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, is pleased to announce that it has closed a […]

NervGen Pharma Reports Third Quarter 2021 Results

Vancouver, Canada. November 18, 2021 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the third quarter ended September 30, 2021. “Most notably, we made important progress […]

The Perks and Pitfalls of Accessible Parking

By Codi Darnell November 16, 2021 “I’m only in it for the parking.” ‍ Whether it’s written on a t-shirt or a bumper sticker, it’s an easy joke for many of us in the disabled community to make. When you enter a packed parking lot and see an empty spot with that bright blue square […]